2018 Colitis Drug Development- Pipeline Analysis Report

April 2018 | | ID: 2FAFFFC50C4EN
VPAResearch

Abstracts

Colitis is a serious inflammation observed in large intestine. Frequent diarrhea and abdominal pain are the main symptoms of the disease. Symptoms tend to appear from few weeks to several years.

Over 40 companies and universities are focusing on developing treatment options for Colitis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Colitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Colitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Colitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 COLITIS PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Colitis Pipeline Snapshot
2.3 Colitis Pipeline by Phase
2.4 Colitis Pipeline by Company
2.5 Colitis Pipeline by Mechanism of Action

3 COLITIS- COMPANY WISE PIPELINE ANALYSIS

Affilogic
Ajinomoto Co Inc
Akebia Therapeutics
Apollo Endosurgery Inc
Brigham Young University Inc
Bristol-Myers Squibb Co
Concenter BioPharma Silkim Ltd
Conseil National de Rechereche en Sante (CNRS) du Senegal
Cosmo Pharmaceuticals NV
Crinos SpA
CSA Biotechnologies LLC
Dr. Falk Pharma GmbH
EA Pharma Co Ltd
enGene Inc
FairJourney Biologics
GeneFrontier Corp
Genfit SA
Hadasit Medical Research Services and Development Ltd
Immuron Ltd
James Cook University
Kissei Pharmaceutical Co Ltd
Koutif Therapeutics LLC
MorphoSys AG
Nankai University
Ogeda SA
Pfizer Inc
RDD Pharma Ltd
RIKEN
Riptide Bioscience Inc
Salix Pharmaceuticals Ltd
Saniona AB
Sigmoid Pharma Ltd
Synovo GmbH
Tel Aviv University
TPCera Ltd
Vedanta Biosciences Inc
Vitality Biopharma Inc

4 COLITIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN COLITIS PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Colitis Pipeline by Phase, H1- 2018
Figure 2: Colitis Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Colitis Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

Table 1: Colitis Pipeline by Phase, H1- 2018
Table 2: Colitis Pipeline by Companies, H1- 2018
Table 3: Colitis Pipeline by Mechanism of Action, H1- 2018
Table 4: Affilogic Colitis Pipeline, May 2018
Table 5: Ajinomoto Co Inc Colitis Pipeline, May 2018
Table 6: Akebia Therapeutics Colitis Pipeline, May 2018
Table 7: Apollo Endosurgery Inc Colitis Pipeline, May 2018
Table 8: Brigham Young University Inc Colitis Pipeline, May 2018
Table 9: Bristol-Myers Squibb Co Colitis Pipeline, May 2018
Table 10: Concenter BioPharma Silkim Ltd Colitis Pipeline, May 2018
Table 11: Conseil National de Rechereche en Sante (CNRS) du Senegal Colitis Pipeline, May 2018
Table 12: Cosmo Pharmaceuticals NV Colitis Pipeline, May 2018
Table 13: Crinos SpA Colitis Pipeline, May 2018
Table 14: CSA Biotechnologies LLC Colitis Pipeline, May 2018
Table 15: Dr. Falk Pharma GmbH Colitis Pipeline, May 2018
Table 16: EA Pharma Co Ltd Colitis Pipeline, May 2018
Table 17: enGene Inc Colitis Pipeline, May 2018
Table 18: FairJourney Biologics Colitis Pipeline, May 2018
Table 19: GeneFrontier Corp Colitis Pipeline, May 2018
Table 20: Genfit SA Colitis Pipeline, May 2018
Table 21: Hadasit Medical Research Services and Development Ltd Colitis Pipeline, May 2018
Table 22: Immuron Ltd Colitis Pipeline, May 2018
Table 23: James Cook University Colitis Pipeline, May 2018
Table 24: Kissei Pharmaceutical Co Ltd Colitis Pipeline, May 2018
Table 25: Koutif Therapeutics LLC Colitis Pipeline, May 2018
Table 26: MorphoSys AG Colitis Pipeline, May 2018
Table 27: Nankai University Colitis Pipeline, May 2018
Table 28: Ogeda SA Colitis Pipeline, May 2018
Table 29: Pfizer Inc Colitis Pipeline, May 2018
Table 30: RDD Pharma Ltd Colitis Pipeline, May 2018
Table 31: RIKEN Colitis Pipeline, May 2018
Table 32: Riptide Bioscience Inc Colitis Pipeline, May 2018
Table 33: Salix Pharmaceuticals Ltd Colitis Pipeline, May 2018
Table 34: Saniona AB Colitis Pipeline, May 2018
Table 35: Sigmoid Pharma Ltd Colitis Pipeline, May 2018
Table 36: Synovo GmbH Colitis Pipeline, May 2018
Table 37: Tel Aviv University Colitis Pipeline, May 2018
Table 38: TPCera Ltd Colitis Pipeline, May 2018
Table 39: Vedanta Biosciences Inc Colitis Pipeline, May 2018
Table 40: Vitality Biopharma Inc Colitis Pipeline, May 2018